Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENSURE-2: IMU-838 (vidofludimus calcium) in adults with relapsing multiple sclerosis
2021-000029-28Phase 3Active
- Sponsor
- Immunic Therapeutics
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing IMU-838 (vidofludimus calcium) with Placebo (2 arms). Primary endpoint: Time to first confirmed relapse. Started May 2022; status: active.
02
Drugs
vidofludimus calcium
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2021-000029-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000029-28.